BGB-53038

Phase 1Small molecule

BeiGene

BGB-53038 is one of 3 small molecule programs targeting Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Solid TumorsTerminated

Metastatic Solid TumorsPhase 1

Terminated

Competition

Competitive Landscape

4 competitors in Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 1

1 2

Erbitux

IImclone

Phase 1

1 3

BGB-53038

BeiGene

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Solid Tumors1 trial

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications

Terminated· BeiGene logo

BeiGene·Phase 1·NCT06585488·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BGB-53038. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-53038 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-53038. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BeiGene

BGB-53038

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News